The rate of cancer survival is expected to keep climbing in coming years largely thanks to research discoveries that are translating into new cancer drugs, which currently account for roughly 30 percent of the pharmaceutical dollar, the chief scientific officer at Bristol-Myers Squib recently said at a showcase event for the UCSF Helen Diller Family Comprehensive Cancer Center.
December 06, 2012
November 06, 2012
Hospitalized heart failure patients who received the drug, serelaxin, in a phase III clinical trial had fewer disease symptoms and as a group experienced 37 percent fewer deaths over six months, according to results of a new study.
September 04, 2012
Pharmaceutical companies now have a guide — the UCSF-FDA TransPortal — to pre-clinical studies they should conduct to identify potentially harmful interactions between existing and new drugs that depend on how the drugs move into and out of cells through protein portals known as transporters.
July 01, 2012
People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when. And for far too many, it happens far too soon.
June 14, 2012
A new approach to drug design, pioneered by a group of researchers at UCSF and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.
June 11, 2012
A new set of computer models has successfully predicted negative side effects in hundreds of current drugs, based on the similarity between their chemical structures and those molecules known to cause side effects, according to a paper appearing online this week in the journal Nature.
May 09, 2012
Continuing a popular but controversial treatment for osteoporosis could reduce spine fracture risk for a particular group of patients, but others could see little to no change if they discontinue it, according to a researcher at UCSF.
May 04, 2012
Academic medical centers can play a larger role in drug development and testing, according to an FDA official, who says there is a need for better strategies to identify winners, minimize costs and reduce failures during drug development.
May 03, 2012
A popular smoking cessation medication has been under a cloud of suspicion ever since the Canadian Medical Association Journal published a study in July 2011 reporting “risk of serious adverse cardiovascular events associated with varenicline.” UCSF researchers, however, question the way the previous study was conducted, and their new analysis, scheduled to be published May 4 in BMJ, reaches a very different conclusion.
April 09, 2012
A UCSF-led effort to create an implantable artificial kidney for dialysis patients has been selected as one of the first projects to undergo more timely and collaborative review at the Food and Drug Administration.